EMD-43593

Single-particle
3.21 Å
EMD-43593 Deposition: 02/02/2024
Map released: 01/05/2024
Last modified: 30/10/2024
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links

EMD-43593

Langya Virus attachment (G) glycoprotein with K85L/L86K mutation

EMD-43593

Single-particle
3.21 Å
EMD-43593 Deposition: 02/02/2024
Map released: 01/05/2024
Last modified: 30/10/2024
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Sample Organism: Langya virus
Sample: Langya virus attachment (G) protein
Fitted models: 8vwp (Avg. Q-score: 0.543)

Deposition Authors: Gibson CG, McCallum MM, Veesler DV
Structure and design of Langya virus glycoprotein antigens.
Wang Z , McCallum M , Yan L , Gibson CA, Sharkey W, Park YJ , Dang HV , Amaya M, Person A, Broder CC , Veesler D
(2024) PNAS , 121 , e2314990121 - e2314990121
PUBMED: 38593070
DOI: doi:10.1073/pnas.2314990121
ISSN: 1091-6490
ASTM: PNASA6
Abstract:
Langya virus (LayV) is a recently discovered henipavirus (HNV), isolated from febrile patients in China. HNV entry into host cells is mediated by the attachment (G) and fusion (F) glycoproteins which are the main targets of neutralizing antibodies. We show here that the LayV F and G glycoproteins promote membrane fusion with human, mouse, and hamster target cells using a different, yet unknown, receptor than Nipah virus (NiV) and Hendra virus (HeV) and that NiV- and HeV-elicited monoclonal and polyclonal antibodies do not cross-react with LayV F and G. We determined cryoelectron microscopy structures of LayV F, in the prefusion and postfusion states, and of LayV G, revealing their conformational landscape and distinct antigenicity relative to NiV and HeV. We computationally designed stabilized LayV G constructs and demonstrate the generalizability of an HNV F prefusion-stabilization strategy. Our data will support the development of vaccines and therapeutics against LayV and closely related HNVs.